Detail akcie Molecular Partn N online

Business Summary: Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Molecular Partners AG revenues decreased 96% to SF7M. Net loss totaled SF62M vs. income of SF117.9M. Revenues reflect Switzerland segment decrease of 96% to SF7M, United States segment decrease from SF9.7M to SF0K. Net loss reflects Net foreign exchange loss increase from SF0K to SF5.1M (expense), Net Foreign Exchange Gain decrease from SF717K (income) to SF0K.